Authored By: Sarah
11 Jul 2024

 Antithrombotic Drugs Market Size to grow by USD 21783.8 million between 2024-2028

According to a research report “ Antithrombotic Drugs Market” by Route Of Administration (Oral, Injectable) Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 21783.8 million, at a CAGR of  7.68% during the forecast period. The global prevalence of cardiovascular disorders, kidney disorders, and strokes, driven by unhealthy lifestyles and insufficient physical activity, has resulted in a significant increase in the incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE). These conditions, which involve the formation of blood clots obstructing normal blood flow, pose a substantial health risk. According to the Centers for Disease Control and Prevention (CDC), approximately 33% of patients with DVT or PE will develop the condition within a decade of initial treatment. Furthermore, the rising number of surgeries for various diseases, including DVT and PE, heightens the risk of developing DVT. Consequently, the growing prevalence of these diseases is anticipated to fuel the expansion of the antithrombotic market during the forecast period.

Browse market data tables, figures, and in-depth TOC on “Antithrombotic Drugs Market” by Route Of Administration (Oral, Injectable) Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Route Of Administration, the Oral segment is projected to dominate the market size in 2024

The Antithrombotic Drugs Market represents a significant business opportunity due to the rising prevalence of cardiovascular diseases and increasing awareness about their prevention. Key players in this market include Daiichi Sankyo, Sanofi, and Bristol-Myers Squibb. These companies are investing heavily in research and development to launch innovative antithrombotic drugs, thereby expanding their product portfolios and strengthening their market positions. Additionally, the growing preference for oral anticoagulants over traditional injectable therapies is expected to drive market growth.

By Distribution Channel, Hospital pharmacy  segment is expected to hold the largest market size for the year 2024

The Antithrombotic Drugs Market represents a significant business opportunity due to the rising prevalence of cardiovascular diseases and increasing awareness of thrombosis prevention. Key players in this market include Daiichi Sankyo, Sanofi, and Bristol-Myers Squibb, who offer a range of anticoagulants and antiplatelet agents. Market growth is driven by the approval of novel therapies, increasing demand for oral anticoagulants, and expanding applications in various therapeutic areas.

North America is forecasted to hold the largest market size by region in 2024

The Antithrombotic Drugs Market represents a significant business opportunity due to the increasing prevalence of cardiovascular diseases and growing awareness of thrombosis prevention. Key players in this market include Daiichi Sankyo, Sanofi, and Bristol-Myers Squibb. These companies leverage innovative technologies and strategic collaborations to offer effective antithrombotic solutions, driving market growth. The market is expected to expand at a robust CAGR through 2027.

The Antithrombotic Drugs Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • AbbVie Inc.
  • Aspen Pharmacare Holdings Ltd.
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Fresenius Kabi AG
  • GlaxoSmithKline Plc
  • Hikma Pharmaceuticals Plc
  • Johnson and Johnson Services Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

Antithrombotic drugs are a crucial class of medications used to prevent and treat cardiovascular events, including venous and arterial thrombosis, in patients with cardiovascular diseases and diabetes. These drugs work by inhibiting various mechanisms of blood clotting, such as thrombolytic medications that dissolve existing clots and antiplatelet medications that prevent platelets from sticking together and forming new clots. Pharmaceutical advancements have led to the development of various antithrombotic agents, including Direct Thrombin Inhibitors, Glycoproteins, Vitamin K Antagonists, Heparins, and Aspirin. The aging and geriatric population, with their increased susceptibility to chronic diseases and cardiovascular events, are a significant market for antithrombotic drugs. Cardiovascular diseases, such as coronary artery disease and stroke, are the leading causes of death and disability worldwide. Diabetes, another chronic disease, also increases the risk of cardiovascular events. Antithrombotic drugs, including Thrombolytic drugs and Anticoagulant drugs, play a vital role in preventing and treating these conditions. Hydroxychloroquine, vaccines, and Vitamin K are also used in the prevention and treatment of thrombosis. Blood clots, or thrombus, can form in both veins and arteries, leading to various complications. Antithrombotic drugs are essential in preventing and treating these conditions, making them a vital segment of the pharmaceutical industry.

Market Research Overview

Antithrombotic drugs are a crucial class of medications used to prevent and treat various cardiovascular disorders, including heart-related ailments, hypertension, cardiovascular diseases (CVDs), diabetes, and cancer. The rising prevalence of sedentary lifestyles, chronic diseases, obesity, and genetic disorders has led to an increase in thrombotic events, such as stroke, pulmonary embolism, deep vein thrombosis, and arterial thrombosis. The high healthcare costs associated with these conditions have led to reimbursement policies that favor the use of antithrombotic agents, including thrombolytic medications, antiplatelet medications, and anticoagulants. Government measures, such as subsidies and insurance coverage, also play a significant role in increasing access to these drugs. Pharmaceutical advancements have led to the development of various antithrombotic agents, including Direct Thrombin Inhibitors, Glycoproteins, Vitamin K Antagonists, Heparins, Aspirin, and Hydroxychloroquine. These drugs work by inhibiting blood clotting mechanisms, preventing the formation of thrombus or dissolving existing clots. The aging population and the increasing prevalence of chronic diseases have led to a significant demand for antithrombotic drugs. However, the high cost of these medications and the need for regular monitoring and dosage adjustments pose challenges to their widespread use. In conclusion, antithrombotic drugs are essential in preventing and treating various cardiovascular problems, including CVDs, stroke, and thrombotic events. The increasing burden of these conditions, coupled with the availability of effective antithrombotic agents, is driving the growth of the antithrombotic drugs market. However, the high cost of these medications and the need for regular monitoring and dosage adjustments remain significant challenges.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio